Biofrontera (NASDAQ:BFRI) Announces Earnings Results

Biofrontera (NASDAQ:BFRI) announced its quarterly earnings data on Thursday. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.19, FiscalAI reports. Biofrontera had a negative return on equity of 1,104.09% and a negative net margin of 47.28%.The firm had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $16.15 million.

Here are the key takeaways from Biofrontera’s conference call:

• Record financial performance: Q4 revenue was $17.1M (up ~36% YoY) and FY revenue was $41.7M (up ~12%); Q4 Adjusted EBITDA was $4.9M and net income was $5.6M, marking the company’s first highly profitable quarter under the new cost structure.
• Strategic U.S. asset acquisition: Biofrontera acquired all U.S. rights, the NDA/IND, patents and manufacturing for Ameluz/RhodoLED and moved to a 12%/15% earn‑out royalty that has already cut COGS and drove Q4 gross margin to ~82% with guidance of 80–85% in 2026.
• Clinical and regulatory momentum: sNDA for superficial basal cell carcinoma was accepted with a PDUFA date of Sept 28, 2026, plus positive Phase III AK extremities results (sNDA planned Q3 2026) and positive Phase II acne data with Phase III planning discussions slated for Q3 2026.
• Commercial traction: Ameluz unit volumes rose ~10% to ~121,000 tubes in 2025, the installed RhodoLED base reached ~745 lamps, churn hit multiyear lows, 150+ new accounts were opened, and an inside‑sales rollout is planned after a successful pilot.
• Liquidity and outlook: Cash was $6.4M at year‑end after raising $11M in Series C preferred and $3M from the Xepi sale, but operating cash use was $13.4M in 2025—management expects 2026 to benefit from the new cost structure and move toward cash‑flow breakeven, making liquidity a watch item.

Biofrontera Stock Down 2.8%

NASDAQ BFRI traded down $0.02 on Thursday, hitting $0.84. The stock had a trading volume of 492,713 shares, compared to its average volume of 530,378. The company’s 50-day moving average is $0.87 and its two-hundred day moving average is $0.88. Biofrontera has a one year low of $0.54 and a one year high of $1.19. The stock has a market cap of $9.83 million, a price-to-earnings ratio of -0.52 and a beta of 0.61.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. 10.08% of the stock is currently owned by institutional investors and hedge funds.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.